Masters of Pediatric Dermatology February 8-9, 2024 Miami Beach, FL

Activity Overview

There are various challenges in the management of pediatric patients with various dermatologic conditions, including acne vulgaris, atopic dermatitis, alopecia areata, epidermolysis bullosa, hidradenitis suppurativa, molluscum contagiosum. psoriasis, and vitiligo. Clinicians are in need of up-to-date education on the latest guidelines and diagnostic tools for early and accurate diagnosis of these conditions, the clinical safety and efficacy of new and emerging therapeutic agents, and expert treatment recommendations for improved pediatric patient care and treatment plan design. The 32nd Annual MOPD Symposium will provide attendees with the latest treatment approaches, protocols, procedures, and tools needed to support children and adolescents with dermatologic conditions, and ultimately provide better, more personalized care for this specific population of younger patients.

Target Audience

The Masters of Pediatric Dermatology symposium is designed to meet the needs of pediatric dermatologists, pediatricians, family practitioners, dermatologists, physician assistants, nurses/nurse practitioners and residents in these programs.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

- Discuss up-to-date expert recommended treatments for pediatric Acne, including clinical safety and efficacy data.
- Examine current and emerging agents for treatment of Alopecia Areata in children.
- Discuss evidence-based strategies to implement existing and newer therapies indicated to treat pediatric Atopic Dermatitis (AD).
- Interpret the clinical efficacy and safety of current and emerging therapies for treatment of Epidermolysis Bullosa (EB) in pediatric
 patients.
- Review updated expert guidance for the diagnosis and treatment of Hidradenitis Suppurativa (HS), including emerging therapeutic
 options for pediatric patients.
- Discuss new and emerging treatment protocols for pediatric patients with Molluscum Contagiosum.
- Review expert recommendations for treatment of pediatric Psoriasis, including those for new and emerging biologic therapies.
- Apply updated clinical data to optimize treatment of pediatric patients with Vitiligo using newly available therapies.

Criteria for Success

Statements of credit will be awarded based on the participant's attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.southbeachsymposium.org. You must participate in the entire activity to receive credit. If you have questions about this CE activity, please contact AKH Inc. at <u>tbrignoni@akhcme.com</u>.



Credit provided by AKH Inc., Advancing Knowledge in Healthcare



In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 10.5 AMA PRA Category 1 Credit(s)^M. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse

10.5 ANCC contact hours.

Physician Assistant



AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 10.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Commercial Support

Full notification of commercial support will be provided in the final course syllabus.